The Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA-2) protein is essential for the immortalization of human primary B cells by EBV. EBNA-2 trans-activates cellular and viral genes like CD23, c-fgr, latent membrane protein 1 (LMP1) and terminal protein 1 (TP1). Transactivation of the TP1 promoter and of the BamHI C promoter has already been investigated in detail and appears to be mediated via protein-protein interactions and not by direct binding of EBNA-2 type A (of EBV type l) to the DNA. EBNA-2 is able to trans-activate the expression of the LMP gene in several cell lines. Various reports have delineated the cis-acting elements of the LMP promoter through which EBNA-2 mediates transactivation. To determine whether EBNA-2 also transactivates the LMP promoter by protein-protein interactions, we performed a series of gel retardation assays and competition experiments with LMP promoter fragments of different sizes. We determined that the protein-binding region on the LMP promoter was within a 42 bp fragment encompassing nucleotides -135 to -176 relative to the LMP transcriptional start site. None of the DNA fragments investigated indicated interaction of EBNA-2 with the DNA via proteinprotein interactions. No significant differences between EBNA-2-positive and EBNA-2-negative nuclear extracts could be seen in the gel retardation assay under conditions that clearly showed binding of EBNA-2A to the TP 1 promoter. However, analysis of sucrose gradient fractions in the gel retardation assay provided evidence that the LMP promoter-binding proteins form a complex of higher Mr in EBNA-2-positive cell extracts. These complexes were destroyed by detergent. We deduce from these results that EBNA-2-positive cells might indeed contain specific complexes bound to the LMP promoter which are, however, too labile to be detected in a standard gel retardation assay.
Introduction
Epstein-Barr virus (EBV) is the causative agent of infectious mononucleosis and induces B cell lymphoproliferative disorders in immunocompromised or genetically susceptible humans. The virus is associated with several human malignancies, for example the endemic form of Burkitt's lymphoma (BL) and epithelial nasopharyngeal carcinoma (NPC; reviewed in Miller, 1990) . The role of the virus in the aetiology of these cancers has not yet been elucidated. More recently, the detection of the genome of EBV in Hodgkin's lymphoma has been reported in 30 to 60 % of cases (Anagnostopoulos et al., 1989; Herbst et al., 1991; Weiss et al., 1989) . In vitro, EBV immortalizes B lymphocytes efficiently. The infection of primary B lymphocytes results in a persistent latent infection and the EBV-carrying lymphoblastoid cell lines are characterized by the expression of only 10 out of more than 100 genes encoded by the virus. Among these genes, six code for nuclear proteins, Epstein-Barr virus nuclear antigen (EBNA)-I, -2, -3a, -3b, -3c and EBNA-LP. Three genes code for membrane proteins, latent membrane protein 1 (LMP1) and terminal proteins 1 and 2 (TP1 and TP2, alternatively called LMP2A and LMP2B). Moreover, two small RNAs, called EBERs, are expressed (reviewed in Kieff & Liebowitz, 1990) . The biological activities of some of the proteins of the EBNA complex are still unknown. LMP1 appears to be the oncogene of the virus, because LMP expression in certain established rodent cell lines induces the transformed phenotype and renders those cells tumourigenic in nude mice (Wang et al., 1985) . EBNA-2 is essential for B cell immortalization and transformation, since the EBV strains P3HR1 and Daudi, which carry a deletion in the EBNA-2 and in part of the EBNA-LP genes, are unable to immortalize B lymphocytes (Jones et al., Bornkamm et al., 1982) . Reconstruction of the P3HR1 deletion with cloned EBV DNA fragments containing the EBNA-2 but not the EBNA-LP gene restores the transforming phenotype (Hammerschmidt & Sugden, 1989) . There are differences in the efficiency of growth transformation between the two subtypes of EBV , and EBNA-2 is one of several genes that differ between virus of type 1 and type 2 (Dambaugh et al., 1984; Sample et al., 1990; Zimber et al., 1986) . B cell growth transformation in EBNA-2A (type 1)-expressing isogenic recombinants is more efficient than in EBNA-2B (type 2)-containing recombinants (Cohen et al., 1989) . EBNA-2 appears to play the role of a trans-activator of cellular and viral proteins, but the biochemical mode of action of the protein in immortalization of B lymphocytes remains to be determined. EBNA-2 is able to stimulate the expression of the B cell activation markers CD21 and CD23 (Aman et al., 1990; Calender et al., 1987 Calender et al., , 1990 Cordier et al., 1990; Wang et al., 1987) and it increases the level of RNA of the c-fgr proto-oncogene (Knutson, 1990) . EBNA-2 trans-activates the viral promoter of TP1 (Zimber-Strobl et al., 1991) and is able to stimulate a lymphoid-specific enhancer in the EBV BamHI C promoter (Sung et al., 1991). EBNA-2 also confers resistance to the antiproliferative effect of interferon-0~ in EBV-negative cells (Kanda et al., 1992) . Expression of EBNA-2 alone in BL cells leads to growth in tight clumps and upregulation of the B cell activation marker CD23 (Wang et al., 1987) . EBNA-2 is able to trans-activate the expression of LMP 1 (reviewed in Middleton et al., 1991) . EBV-negative BL cell lines that were converted with the EBV strain B95-8 express LMP1 whereas P3HRl-converted BL cell lines do not (Murray et al., 1988) . Furthermore, it was shown that the expression of EBNA-2 in several P3HR1-converted BL cell lines results in expression of LMP1 (Abbot et al., 1990; Wang et al., 1990) . However, EBNA-2 is not able to induce LMP expression in all cell lines; it appears to depend on the host cell environment. When EBNA-2 is expressed in P3HRl-infected BL41 cells, no LMP1 expression can be induced (Cordier et aI., 1990) . In contrast, expression of LMP1 is detected in P3HR-l-infected BJAB cells despite the absence of EBNA-2 expression (Cordier-Bussat et al., 1993) . Therefore, cellular factors could play a decisive role in the regulation of the expression of LMP. In NPC cells, which are of epithelial origin, EBNA-2 is not expressed, but LMP is expressed in about 65 % of cases (Fahraeus et al., 1988) . The mechanism of trans-activation of the TP1 promoter by EBNA-2 was investigated in detail by Zimber-Strobl et al. (1993) . It was shown that EBNA-2 interacts with its cognate binding site indirectly through protein-protein interactions. More specifically, no direct binding of EBNA-2 to the TPI promoter could be detected. Similar results were reported for the EBNA-2-responsive region of the BamHI C promoter (Ling et al., 1993) . While it is well documented that the cis-acting DNA sequences upstream of the CD23 promoter and the LMP promoter (Ghosh & Kieff, 1990; Wang et al., 1990; Tsang et al., 1991 ; Fahraeus et al., 1990) respond to EBNA-2, EBNA-2 interaction with a specific DNA sequence or a DNA sequence-specific protein has not been demonstrated. The objective of the experiments presented here was to elucidate whether EBNA-2 interacts with the LMP promoter via proteinprotein interactions as it does in case of the TP1 promoter. We used a gel retardation assay to study this. We also wanted to know whether there are differences between epithelial cells and B cells in the binding of proteins to the LMP promoter.
Here, we show that there were no detectable differences in the protein binding pattern between EBNA-2-positive and EBNA-2-negative nuclear extracts when analysed in the gel retardation assay under conditions that revealed indirect binding of EBNA-2A to the TP1 promoter. However, when we analysed cell extracts separated by sucrose gradient centrifugation we found that the LMP promoter-binding proteins form a complex of higher M r in the EBNA-2-positive cell extracts. Furthermore we show that there are differences between B cell and epithelial cell proteins in their binding to the LMP promoter.
Methods
Cell lines and culture conditions. The cell lines M-ABA, M-ABA/CBL, Jijoye and P3HR1 have been described elsewhere (Crawford et al., 1979; Jeang & Hayward, 1983; Zimber et al., 1986; Hinuma et al., 1967) . IB4 (King et al., 1980) was derived by transforming human placental lymphocytes with the B95-8 EBV strain. M-ABA is a marmoset cell line established by cocultivation of B lymphocytes with EBV derived from a NPC, while M-ABA/CBL was established by immortalizing human cord blood lymphocytes with the M-ABA strain virus. BL41-P3HR1 was obtained after infection of the EBV-negative cell line BL41 with the virus strain P3HR1 (Calender et al., 1987) . M-ABA, M-ABA/CBL and IB4 contain type 1 EBV. Jijoye is a cell line derived from a BL infected with the prototype of type 2 strain of EBV (Hinuma et al., 1967; Bornkamm et al., 1982) . M-ABA, 1B4 and Jijoye express EBNA-2 whereas the P3HR1 subclone of Jijoye harbours a non-transforming EBV genome that has a deletion in the EBNA-2 and EBNA-LP genes (Hinuma et al., 1967; Bornkamm et al., 1982) . BJAB is an EBV-negative B cell line (Klein et al., 1974) . All lines were subcultured routinely once or twice per week in RPMI-1640 medium (Seromed) supplemented with 10 % fetal calf serum (Seromed), 2 mM-L-glutamine, penicillin (40 units/ml), streptomycin (50 ~g/mI), moronal (nystatin, 10 units/ml) and neomycin sulphate (10 gg/ml), HeLa cells and the keratinocytic cell line HaCaT (Boukamp et al., 1988) were maintained in Dulbecco's modified Eagle's MEM supplemented with 10% fetal calf serum, penicillin (100 units/ml) and streptomycin (50 gg/ml). In order to determine the sedimentation values in sucrose gradient experiments, the simian virus 40 (SV40) large T antigen-expressing cell line C57/SV (kindly provided by G. Brandner, Freiburg, Germany) was cultured in Dulbecco's modified Eagle's MEM supplemented with 3 % fetal calf serum and the antibiotics as described above.
In vitro transcription and translation experiments. Expression of EBNA-2 in vitro was carried out essentially as described elsewhere (Zimber-Strobl et al., 1993) .
Sucrose gradients. Sedimentation experiments were carried out essentially as described (Grfisser et al., 1991) , except that approximately 230 lag of detergent-free nuclear extract instead of whole cell extracts was used. Fifteen to 16 fractions were collected and 12 gl of each fraction was used for the gel retardation assay. The remainder of the fractions were precipitated with ethanol, separated by SDS-PAGE and analysed by immunoblotting as described previously (Grg.sser et al., 1991) ; EBNA-2A was detected with a specific polyclonal serum (Billaud et al., 1989) .
In order to determine the sedimentation values, extracts of the SV40 large T antigen-expressing cell line C57/SV were routinely analysed in parallel, as described previously (Grfisser et al., 1991; Schickedanz et al., 1986) . Briefly, the fractions were precipitated with ethanol and stained after blotting onto a nitrocellulose filter using the T antigenspecific antibody PAb1605 generously provided by G. Brandner. The data shown are representative results obtained in four different experiments.
Nuclear extract preparation. Nuclear extracts were prepared by a modification of the method of Dignam et al. (1983) . The pellet (4 x 107 to 3 x 108 cells) was washed twice in ice-cold PBS, resuspended with three to four volumes of buffer A (10 mM-HEPES pH 7.9, 10 mN-KCI, 1.5 mM-MgC12, 5 mM-DTT and 0.5 mM-PMSF) and incubated on ice for 1 h. All subsequent steps were carried out on ice. The swollen cells were disrupted by Dounce homogenization (10 to 15 strokes) until approximately 90 % of the cells were broken. Nuclei were then pelleted by centrifugation for 10 s in a microcentrifuge and washed once in buffer A. They then were resuspended in three volumes of buffer B (20 mM-HEPES pH 7-9, 420 mM-NaCI, I-5 mM-MgCI2, 0-2 mta-EDTA, 5 mM-DTT, 0-5 mM-PMSF and 20% v/v glycerol). After incubation on ice for 30 rain, the lysed nuclei were clarified by a 20 rain centrifugation at 12000 g and 4 °C. The supernatant was frozen and stored as aliquots in liquid nitrogen. The protein concentration was determined by the Bradford method (Bradford, 1976) . To disrupt protein-protein interactions, 0-5 % NP40 or NP40 and 0-6 % deoxycholic acid (DOC) were added to the buffer B. The nuclei were then treated as described above.
Oligonucleotides, DNA and radiolabelling. For gel retardation assays the LMP promoter was obtained by digesting the subclone G27-14 derived from the M-ABA cosmid clone 302-23 (Polack et al., 1984) with This fragment, spanning the region from -129 to -246, was used for further bandshift assays and competition experiments and was subdivided into six small overlapping DNA fragments, oligonucleotides 1 to 6 (e). These double-strauded oligouucleotides were used for gel retardation assays and for competition experiments.
the restriction endonucleases SauI and Bali. These restriction sites are found at nucleotide positions 169480 and 169747, respectively, of the EBV prototype genome B95-8 (Baer et al., 1984) . The LMP promoter was labelled with T4 DNA polymerase in the presence of [~-32P]dGTP. Competition experiments for analysing the specificity of DNA binding at the LMP promoter fragment defined above were carried out using unlabelled PCR-amplified fragments of the LMP promoter ( Fig. 1 ). For PCR amplification the following primers were used, corresponding 
to the nucleotides of the B95- (Baer et al., 1984) and has the following sequence: 5' CTCGCGACTCGTGGGA-AAATGGGCGGAAGGGCACCGTGGGAAAATAGTTCCAGG 3'. The Y-protruding ends were filled in with the Klenow fragment of DNA polymerase 1 (Boehringer Mannheim) in the presence of [~-a2p] dGTP. The double-stranded oligonucleotides used for gel retardation assays were obtained by annealing the oligonucleotide pairs given in Table 1 . Each single-stranded oligonucleotide was purified by TLC. The protruding ends of the annealed oligonucleotides were filled in with the Klenow fragment in the presence of [~-32P]dGTP, dCTP, dATP and dTTP for gel retardation assays and of dGTP, dCTP, dATP and dTTP for competition experiments.
Band shift analysis. Binding reactions (20 lal) were carried out by preincubating either 2.5 lag of crude nuclear extracts (0.5 to 1 gg for bandshift assays with the BalI-SalI LMP promoter fragment) or 12 gl aliquots of fractionated extracts obtained by sucrose density centrifugation for 15 min at 25 °C in binding buffer [10 mM-HEPES-KOH pH 7.9, 50 mM-KC1, 1 mN-EDTA, 1 mM-DTT, 0-1 mM-PMSF, 2 lag poly(dI-dC) (Pharmacia), 40 lag BSA and 0.4% w/v Ficoll-400 (Pharmacia)]. After the addition of 0.1 to 1.4 ng (20 000 to 25000 c.p.m.) of radiolabelled DNA, the samples were incubated at 25 °C for a further 30 min. The samples were separated by electrophoresis overnight at room temperature in 4% to 5% polyacrylamide gels in 1 x TBE running buffer (89 mM-Tris-borate pH 8.3, 2-5 mM-EDTA) and analysed by autoradiography. For competition and supershift experiments, either unlabelled oligonucleotide or 3 gl of tissue culture supernatant containing monoclonal antibody was added to the reaction mixture. The anti-EBNA-2 monoclonal antibody was R3 (rat IgG2a; Zimber-Strobl et al., 1993) ; anti-mouse CD45 (rat IgG2a) was used as an isotype control antibody. In complementation experiments, 3 lal of in vitro-translated EBNA-2 protein or in vitro-translated Brome mosaic virus RNA was added to the reaction mixture. defined between positions -2 3 4 and -9 2 , whereas the region between positions -2 3 4 and -205 has been described as being essential for EBNA-2 responsiveness . Ghosh & Kieff (1990) defined two positive cis-activating LMP promoter regulatory components ( -155 to -147 and -2 3 4 to -205). An EBNA-2-responsive element has also been mapped to the -2 1 4 to -144 LMP promoter region (Fahraeus et al., 1993) . Thus far there have been no DNA binding data published concerning the LMP1 promoter region. By using the gel retardation assay, we wanted to map the region where the putative transcription factors bind and to find out 1 2 3 4 5 6 7
Results

Several protein complexes bind to an LMP1 promoter fragment independently of EBNA-2
Several series of experiments indicated that there are positive and negative regulatory transcription elements between position -2 3 4 and +37 relative to the LMP transcription start site (Fahraeus et al., 1990; . The region between -5 4 and + 40 appears to contain a constitutively active transcription element and the region from -1 0 6 to -5 4 a negative regulatory element that prevents the activity of adjacent positive elements in the absence of EBNA-2. A cis-acting element through which EBNA-2 trans-activates LMP 1 has been , 1993) . The region between position + 3 7 and -2 3 2 relative to the L M P transcription start site was considered to be suitable for our investigation. Fig. 2 shows the analysis o f different nuclear extracts tested in the gel r e t a r d a t i o n assay using the + 37 to -2 3 2 L M P p r o m o t e r fragment. All B cell lines tested showed qualitatively the same p a t t e r n o f b a n d s : four protein complexes could be observed, the complexes denoted A and B migrated slower than C and 
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says performed with HeLa cell nuclear extracts revealed two protein-DNA complexes (denoted F and G in Fig.  2 ). Both complexes migrated more slowly in the nondenaturing polyacrylamide gel than each of the four protein complexes of the B lymphocyte cell extracts that bound the LMP promoter. However, the LMP promoterprotein complex with the slowest mobility of the analysed protein extracts (complex E) was obtained by using nuclear extract of the keratinocytic cell line HaCaT, as shown in lane 2 of Fig. 2 .
Confining of the protein-binding region to a 42 bp LMP promoter fragment
The fragment used for the gel retardation assays outlined above spanned a large region of the LMP promoter. We next attempted to delineate more precisely the sequence that was responsible for the formation of complexes A to D. Furthermore, we wanted to know whether we could detect a qualitative difference between EBNA-2-positive and -negative cell extracts in the gel retardation assay when using a shorter LMP1 promoter fragment. Therefore, the LMP 1 promoter was subdivided for competition experiments into four overlapping DNA fragments as shown in Fig. 1 . Only competitor DNA encompassing the sequence between nucleotides 169761 and 169644 (amplified with primers C and D; Fig. 1 ) was able to inhibit the binding of proteins to the radiolabelled LMP promoter when added in a 10-fold molar excess to the binding reaction mixture (data not shown). This 117 bp fragment corresponds to the region from -129 to -246 relative to the LMP transcription start site. Using this radiolabelled LMP promoter fragment as a probe, extracts of various B cell lines were analysed in a bandshift assay and several protein complexes could be detected (data not shown). The specificity of these complexes was determined by a competition experiment (Fig. 3a) . We wanted to investigate whether EBNA-2 was part of any of these complexes. With nuclear extract of the cell line IB4 as a source of EBNA-2A, we performed a supershift experiment with the anti-EBNA-2 monoclonal antibody R3, with the 54 bp TP promoter fragment described by Zimber-Strobl et al. (1993) serving as a positive control (data not shown). No additional retardation (supershift) of any complex could be induced when the radiolabelled 117 bp LMP promoter fragment was used in the gel retardation assay in the presence of the EBNA-2-containing IB4 cell nuclear extract and the anti-EBNA-2 monoclonal antibody R3. Also, the addition of in vitro-translated EBNA-2 to the reaction mixture containing an EBNA-2-negative extract had no effect on the protein-binding pattern (data not shown).
The possibility remained that the use of a still smaller fragment in the gel retardation assay might reveal differences between EBNA-2-positive and EBNA-2-negative extracts. We therefore subdivided the 117 bp LMP promoter fragment into six overlapping DNA fragments as shown in Fig. 1 . All fragments were tested in competition experiments using the radiolabelled 117 bp LMP promoter fragment as a probe. As shown in Fig. 3 (b) , oligonucleotide 5, spanning the region from nucleotides -135 to -176 relative to the transcription In lanes 2, 5, 8 and 11 the anti-EBNA-2 monoclonal antibody R3 (IgG2a) was added to the reaction mixture (ii). In lanes 3, 6, 9 and 12 the isotypic monoclonal antibody anti-mouse CD45 (IgG2a) was added as a control antibody (iii). In lanes 1, 4, 7 and 10 no monoclonal antibody (i) was added. The arrows indicate the EBNA-2-containing complex, which is formed with the TPI promoter in presence of EBNA-2-containing nuclear extract. The addition of the anti-EBNA-2 antibody R3 induced a supershift of the EBNA-2-containing complexes (lane 11). The reactions were separated on a 4 % native polyacrylamide gel.
start site, was able to prevent the binding of proteins to the fragment nearly completely when added in a 120-fold molar excess to the binding reaction mixture. All the complexes that were considered to bind specifically to the 117 bp LMP promoter fragment were not observed in presence of oligonucleotide 5 and the other oligonucleotides were not able to prevent the formation of the complexes mentioned above (data not shown for oligonucleotides 1 to 4).
The 42 bp LMP promoter fragment shows binding of several protein complexes independently of EBNA-2
We investigated the protein-binding behaviour of nuclear extracts of different cell lines using oligonucleotide 5 as probe in the gel retardation assay. As shown in Fig. 4(a) , at least four main protein complexes (denoted A to D) could be observed when nuclear extracts of various B cell lines were used in the assay. No differences in the intensities of the signals of complexes B, C and D could be observed, whereas the intensity of complex A differed among the various B cell lines tested. However, we did not observe a significant difference between EBNA-2-positive and EBNA-2-negative nuclear extracts, since the intensity of the signal of complex A varied considerably among the EBNA-2-positive extracts. Moreover, no qualitative difference between EBNA-2-positive and EBNA-2-negative extracts could be shown by the gel retardation assay. When the EBV-negative B cell line B JAB was used, the four complexes could again be observed (data not shown). Interestingly, the proteinbinding pattern of nuclear extracts of epithelial cell origin differed from those obtained with nuclear extracts of B cell origin when the small 42 bp fragment was used. Complex D was completely absent in extracts of the epithelial cell lines HeLa and HaCaT. Therefore, this complex appeared to be B cell-specific. The signal of complex A was only very weak; complex B was completely absent when extracts of the cell line HaCaT were used. When HeLa cell extracts were used, the signal of complex B was strongly reduced in comparison to B cell extracts. Complex C appeared to migrate slightly faster in the gel and it is possible that these C complexes observed with HeLa and HaCaT cells are not identical to the B cell line C complex (Fig. 4 a) . We have no evidence that the complexes observed with epithelial cell lines and with B cell lines contain identical proteins. The specificity of the B cell complexes A to D was confirmed by competition experiments. Only the addition of unlabelled oligonucleotide 5 to the gel retardation assay reaction mixture in a 100-fold molar excess, in presence of radiolabelled oligonucleotide 5, prevented the formation of all four complexes (Fig. 4b) . When the other oligonucleotides were added as unlabelled competitor DNA, the four complexes were still observed (data not shown for oligonucleotides 1, 2 and 3). The specificity of the complexes obtained with nuclear extracts of epithelial origin could also be shown by a competition experiment (Fig. 4c) . We wanted to investigate whether EBNA-2 is part of any of the complexes seen in the gel retardation assay using the radiolabelled oligonucleotide 5 as a probe. The LMP promoter-derived oligonucleotide 5 was tested in a supershift experiment that also included the TP promoter-derived 54 bp oligonucleotide. The labelled oligonucleotides were incubated either with EBNA-2-deficient or with EBNA-2-containing cell extracts (BL41-P3HR1 and IB4, respectively). Subsequently, the protein-DNA complexes were mixed either with the EBNA-2-specific monoclonai antibody R3, an unspecific control antibody (anti-mouse CD45) or with solution containing no antibody. As described earlier (Zimber-Strobl et al., 1993) , a high M r complex could be observed that was retarded only by the addition of EBNA-2-specific monoclonal antibody. Also, no TP promoter complex was formed with EBNA-2-deficient extracts. In contrast, the oligonucleotide 5 derived from the LMP promoter exhibited no additional bands in the presence of EBNA-2 and no supershift was observed when the EBNA-2-specific antibody was added (Fig. 4 d) . We also tested the other five oligonucleotides in gel retardation assays (data not shown). Only with oligonucleotide 1 (spanning the region from -210 to -246 relative to the transcription start site) could we see a DNA-protein complex that appeared to be specific, because complex formation could be prevented by 100-fold molar excess of unlabelled oligonucleotide 1. This complex was seen with all B cell line extracts tested and no qualitative difference between EBNA-2-positive and EBNA-2-negative nuclear extracts could be detected (data not shown). Supershift assays with the monoclonal anti-EBNA-2 antibody R3 were negative (data not shown).
Complex formation of the LMP promoter-binding protein(s) induced by EBNA-2
From the data described above, we concluded that (i) no qualitative difference between EBNA-2-positive and -negative cell lines was detectable in DNA-binding assays and (ii) that EBNA-2A/-2B was not involved in LMP promoter-binding via the same protein-protein interactions as with TP1 promoter-binding. Cell extracts derived from EBNA-2-positive or -negative cell lines should therefore not show a difference in their DNAbinding behaviour when separated on a sucrose gradient. As demonstrated previously, EBNA-2 exists in two complexed forms, sedimenting in sucrose gradients at approximateiy 13S and 34S (Gr~isser et al., 1991) . We (c) 1 2 3 4 5 6 7 8 9 10 11 1213 1415 30% 5% Sucrose density Fig. 5 . Testing of fractions obtained by sucrose gradient centrifugation in gel retardation assays using the (-232 to +40) LMP promoter fragment as a probe. Nuclear extracts derived from the EBNA-2-negative cell line P3HR1 and the EBNA-2-positive cell lines M-ABA (type A) and Jijoye (type B) were layered on a 5 % to 30 % sucrose gradient and separated by ultracentrifugation as described previously (Grgsser et al., 1991) . Fifteen fractions of 700 lal were collected and a 12 lal sample of each fraction was tested in an LMP promoter binding assay. The numbers of the fractions are indicated, with fraction number 1 corresponding to 30% sucrose and fraction number 15 (top of the gradient) corresponding to 5% sucrose. The cell lines used were P3HR1 (a), M-ABA (b) and Jijoye (c).
tested the L M P promoter-binding activities of the various fractions obtained by sucrose gradient centrifugation carried out with nuclear extracts of the cell lines P3HR1, M-ABA and Jijoye. Because the LMP1 promoter fragment from position -2 3 2 to +37 was the only one with which we observed quantitative differences between EBNA-2-positive and EBNA-2-negative cell lines in gel retardation assays, this fragment was used as radiolabelled probe in the assay. The results revealed that there were differences in the migration of the D N Abinding complexes depending on the presence of EBNA-2 in the cell extracts. In centrifugations carried out with the EBNA-2-negative P3HR1 cell nuclear extract, the peak of the LMP promoter-binding activities reproducibly appeared at the top of the gradient (at the lower sucrose concentration) (Fig. 5) . The main binding activities were obtained in fractions 11 to 13 (Fig. 5a ) corresponding to a sedimentation coefficient of approximately 7S to 8S. In experiments carried out with the EBNA-2-positive nuclear extracts from the cell lines M-ABA or Jijoye, the main LMP promoter-binding activities were observed in fractions 9 to 11, sedimenting at approximately 13S, in both cell lines (Fig. 5b, c) . The fractions that contained the major binding activities in P 3 H R I cell gradients exhibited only weak binding activities, if any, in the EBNA-2-containing cell extracts (for example, lanes 12 to 14 in Fig. 5 ). No retardation of the LMP promoter was obtained in the fractions from high sucrose concentrations (fractions 1 to 7 in EBNA-2-positive and fractions 1 to 9 in EBNA-2-negative cells). These results indicated that the very high M r fractions of the gradients had no binding activity towards the L M P promoter.
Treatment of nuclear extracts with detergents disrupts the higher order L M P promoter-binding and the EBNA-2A-containing complexes
The sedimentation coefficient of approximately 13S for the LMP promoter-binding complex described above is in good agreement with the recently reported value (also approximately 13S) for the EBNA-2 protein obtained from whole cell extracts. In experiments carried out with P3HR1 cell extracts the binding activities were observed in fractions corresponding to a sedimentation coefficient of approximately 7S to 8S. For sucrose density centrifugation, nuclear extracts obtained from the EBNA-2A-expressing cell line M-ABA were treated with either 0'5 % NP40 or 0.6 % D O C in combination with 0'5 % NP40, and aliquots of the gradients were tested in gel retardation assays. Because we did not find any DNAbinding activities in the fractions from higher sucrose concentrations, we only analysed fractions 6 to 15 in the experiments shown in Fig. 6 . In addition, the fractions were precipitated with ethanol and analysed by immunoblotting for the presence of the EBNA-2A protein, as shown in Fig. 6 (b) . As can be seen in Fig. 6 (a) , treatment of the nuclear extracts with 0.5 % NP40 caused a shift of the main LMP promoter-binding activities from between fractions 10 and 12, in the case of untreated cell extract, towards the top of the gradient (fractions 12 to 15). The non-ionic detergent NP40 destroyed the complex sedimenting at approximately 13S (Fig. 6a, i) to probably uncomplexed LMP promoter-binding proteins sedimenting at approximately 6S to 8S (Fig. 6a, ii) . The sedimentation behaviour of the NP40-treated LMP promoter-binding proteins is therefore comparable to the situation obtained using P3HR1 cell nuclear extracts (Fig. 5 a) . The slight shift of one fraction observed when comparing the results of Fig. 5 and Fig. 6 (a) is due to variations in the experimental procedure. An additional treatment of M-ABA cell derived nuclear extract with 0.6 % DOC, which has been shown to disrupt proteim protein interactions (Baeuerle & Baltimore, 1988) , revealed that DOC had no additional effect on LMP promoter-binding (Fig. 6a, iii) . The EBNA-2A-containing protein complex was disrupted by both NP40 and DOC, leading to a sedimentation coefficient for EBNA-2 of about 13S. This is shown in the immunoblots in Fig.  6 (b, ii and iii). This result is in good agreement with the previously described sedimentation behaviour of EBNA-2A (Gr/isser et al., 1991) . The whole-cell extract used in that report was obtained by lysing M-ABA cells with a buffer containing 0'5% NP40. However, EBNA-2A obtained from untreated nuclear extract of M-ABA cells exhibited a sedimentation coefficient of approximately 16S to 17S (Fig. 6b, i) . In summary, the EBNA-2 protein sedimented at about 16S in the absence of NP40, while the peak of DNA-binding activity was found at approximately 13S. Treatment with NP40 resulted in a decrease of both the sedimentation values of EBNA-2 and the DNA-binding activity. Again, we point out that under both sets of conditions, the peak of the EBNA 2 protein and the DNA-binding fractions did not coincide. We note that preincubation of detergent-free extract with NP40 had no effect in a standard bandshift assay using oligonucleotide 5 (data not shown).
Discussion
Thus far, no data have been published concerning the mechanism through which EBNA-2 mediates transactivation of the LMP promoter. We therefore wanted to know whether EBNA-2 interacts with the LMP promoter via protein protein interactions, as it does in the case of the TP1 promoter. By gel retardation studies, we confined the protein-binding region to an oligonucleotide spanning positions -176 to -135 (oligonucleotide 5). This oligonucleotide was bound by four specific DNAprotein complexes when nuclear extracts of B cell lines were used. Testing of the other small oligonucleotides in the gel retardation assay revealed the formation of a specific complex using oligonucleotide 1, spanning the region from -210 to -246. However, this oligonucleotide was not able to compete for the binding of proteins to the 117 bp LMP promoter fragment. Oligonucleotide 1 encompasses a part of the region from -205 to -234, which appears to be essential for EBNA-2 responsiveness Ghosh & Kieff, 1990) . With oligonucleotides 1 and 5 as probes, we could not detect any difference between EBNA-2-positive and EBNA-2-negative nuclear extracts in the gel retardation assay. The binding conditions were identical to those employed for binding of EBNA-2A to the TP1 promoter. From our data we concluded that EBNA-2 transactivates the LMP promoter in another, possibly more indirect, way, as EBNA-2 does in the case of the TP promoter, and not via protein-protein interactions. When separated on a sucrose gradient, cell extracts derived from EBNA-2-positive or -negative cell lines should therefore not show a difference in their DNAbinding behaviour. However, gel retardation assays employing B cell extracts analysed by sucrose gradient density centrifugation revealed a difference between EBNA-2-positive and EBNA-2-negative protein extracts when the -232 to +37 LMP promoter fragment was used for the shifts. In the case of the EBV-positive but EBNA-2-negative cell line P3HR1 the binding activities have been found in the top region of the gradients with low sucrose concentrations (fractions 12 to 13), corresponding to a sedimentation coefficient of approximately 7S to 8S. In contrast, the peak of the DNAbinding activities in the presence of both EBNA-2A and EBNA-2B was detected in regions of higher sucrose concentration (fraction 10) indicating the formation of complexes with higher M r values, corresponding to a sedimentation coefficient of approximately 13S. These data would seem to indicate the presence of a higher Mr complex in EBNA-2-positive cells compared to EBNA-2-negative cells. This finding, however, is not reflected in the migratory behaviour of these complexes in the gel retardation experiment, because the complexes corresponding to 13S should migrate more slowly than the complexes corresponding to 8S. Since this was not the case, one possible explanation could be that the higher order complexes are very labile. To test this hypothesis, the cell extracts were treated with detergent (NP40 or NP40 and DOC). We demonstrated that the complexes sedimenting at approximately 13S were destroyed by NP40 and subsequently migrated at 8S. We also wanted to know whether the peak of the EBNA-2A-containing fractions would coincide with the peak of the LMP promoter-binding activity. When untreated nuclear extract from the EBNA-2A-expressing B cells was used, EBNA-2 sedimented in fractions 6 to 10, whereas the LMP promoter was bound mainly in fractions 10 to 13. Separation of EBNA-2-positive and DNA-binding fractions was never absolute, and it is possible that there were subfractions of the EBNA-2A protein that were associated with the LMP promoter-binding activities. Low amounts of EBNA-2 also could be detected in the DNA-binding fractions. Thus, we cannot definitely exclude the participation of a specially modified subfraction of EBNA-2 in the LMP promoter-binding complex. Alternatively, EBNA-2 might indirectly induce the formation of a very labile DNA-binding complex. The lability of the complexes would lead to their destruction when investigated in the gel retardation assay and therefore they would not be detectable. The observation that even NP40 leads to a destruction of the complex sedimenting at approximately 13S hints at the labile character of the proposed complexes. Fahraeus et al. (1990) and Cordier-Bussat et al. (1993) discuss a model which is compatible with our proposed mechanism of trans-activation. EBNA-2 could directly or indirectly change the balance between positive and negative factors by means of direct binding to a transcription factor or by the induction of an additional factor that would be able to bind to a positive factor.
